Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV P2-VP8 Vaccine Efficacy in Healthy Infants
NCT04010448Phase 3Recruiting
- Sponsor
- PATH
- Start
- Oct 2019
- Primary completion
- Dec 2025
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of trivalent P2-VP8 subunit rotavirus vaccine in rotavirus gastroenteritis, sponsored by PATH. Started Oct 2019; status: recruiting.
02
Drugs
trivalent P2-VP8 subunit rotavirus vaccine
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT04010448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010448.